In order to achieve a radical cure for solid tumors, what aspects of technology do we need to increase investment in? What AI assisted methods are needed?

Despite remarkable advances in cancer immunotherapy, targeted therapy, and surgical techniques, true radical cure for most solid tumors—especially those with high heterogeneity, immunosuppressive microenvironments, and metastatic potential—remains elusive. Incremental improvements are no longer sufficient; we need transformative breakthroughs. From a clinician-scientist perspective working at the intersection of oncology and translational research, I would like to ask the community: Which technology domains should receive the highest priority for funding and research efforts? Are we looking at next-generation CAR-macrophage or TCR-T cell therapies, in vivo gene editing, tumor microenvironment reprogramming, or precision delivery nanocarriers? Equally important, what role should AI play beyond current applications in radiology and pathology? Do we need AI systems capable of real-time intraoperative decision support, multimodal data integration for dynamic treatment adaptation, or computational models that predict resistance evolution at the single-cell level? I am also keen to hear critical views: Are there areas where AI is overhyped relative to its current clinical utility in solid tumor cure? I welcome perspectives from surgical oncology, immuno-oncology, computational biology, and medical AI development. Thank you.